FY2028 EPS Estimates for Cytosorbents Reduced by Analyst

Cytosorbents Corporation (NASDAQ:CTSO) – Investment analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for shares of Cytosorbents in a research note issued on Thursday, March 26th. HC Wainwright analyst S. Lee now forecasts that the medical research company will earn ($0.04) per share for the year, down from their prior forecast of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.02) EPS.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The business had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $9.22 million. Cytosorbents had a negative net margin of 22.12% and a negative return on equity of 131.86%.

CTSO has been the topic of several other research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $0.59 on Monday. The company has a market capitalization of $37.24 million, a P/E ratio of -4.56 and a beta of 1.36. The company’s 50-day moving average is $0.69 and its 200 day moving average is $0.75. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11. Cytosorbents has a fifty-two week low of $0.50 and a fifty-two week high of $1.39.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC grew its holdings in Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Cytosorbents in the third quarter worth about $105,000. CIBC Bancorp USA Inc. bought a new position in shares of Cytosorbents in the third quarter valued at approximately $161,000. Finally, CM Management LLC boosted its position in shares of Cytosorbents by 14.6% in the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock valued at $944,000 after acquiring an additional 188,372 shares during the period. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.